English 
Chinese 
Russian 
French MSC Therapy for Graft-versus-Host Disease: What 15 RCTs and a Biomarker-Guided Trial Tell Us
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.